# Postoperative adjuvant chemotherapy in patients with stage II early onset colorectal cancer: exploration and discovery using real-world data and the SEER database

## TL;DR

This study finds that most stage II early-onset colorectal cancer patients do not benefit from post-surgery chemotherapy, except those with T4 stage tumors.

## Contribution

The study identifies T4 stage as the only subgroup in stage II EOCRC where chemotherapy provides long-term survival benefits.

## Key findings

- Most stage II EOCRC patients showed no survival benefit from adjuvant chemotherapy.
- T4 stage patients receiving chemotherapy had significantly prolonged survival after three years.
- No significant survival differences were found in dMMR, pMMR, or T3 subgroups.

## Abstract

The incidence of early-onset colorectal cancer (EOCRC) is rising, yet intensive postoperative adjuvant chemotherapy (ACT) often results in overtreatment with minimal prognostic benefit. This study aims to assess the therapeutic necessity of ACT in stage II EOCRC patients and to identify potential ACT candidates.

A total of 296 non-ACT and 50 ACT patients with stage II EOCRC were included from Xijing Hospital (XJCRC), and 2067 non-ACT and 1163 ACT patients were enrolled from the Surveillance, Epidemiology, and End Results (SEER) cohort. To address selection bias and confounding, propensity score matching, inverse probability treatment weighting (IPTW), and multivariate Cox regression analyses were utilized. Survival curves and landmark analysis were employed to compare Overall Survival (OS) differences.

Similar OS were observed between ACT and non-ACT groups in both cohorts before and after adjustment for confounders. No significant survival differences were noted in dMMR (P = 0.48), pMMR (P = 0.07), and T3 (P = 0.83) subgroups. However, T4 stage patients receiving ACT demonstrated prolonged survival compared to non-ACT counterparts, particularly after three years (P = 0.007), as identified by landmark analysis.

Most stage II EOCRC patients might yield limited benefits from postoperative ACT, with the sole exception of those at T4 stage, who could experience long-term clinical advantages.

https://clinicaltrials.gov/study/, identifier NCT06308354.